{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:38:07Z","timestamp":1782484687548,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40265-025-02183-z","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:11:05Z","timestamp":1746425465000},"page":"725-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Differentiating IL-23 Inhibitors in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-4785","authenticated-orcid":false,"given":"Olga Maria","family":"Nardone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer K.","family":"Vuyyuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurij","family":"Hanzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"10432","key":"2183_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403(10432):1177\u201391.","journal-title":"Lancet"},{"issue":"3","key":"2183_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","volume":"81","author":"J Hanzel","year":"2021","unstructured":"Hanzel J, Ma C, Vande Casteele N, Khanna R, Jairath V, Feagan BG. Vedolizumab and extraintestinal manifestations in inflammatory bowel disease. Drugs. 2021;81(3):333\u201347.","journal-title":"Drugs"},{"key":"2183_CR3","doi-asserted-by":"crossref","unstructured":"Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: A meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031\u201345.e11.","DOI":"10.1016\/j.cgh.2020.10.039"},{"issue":"1","key":"2183_CR4","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel J-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.","journal-title":"Clin Transl Gastroenterol"},{"issue":"15","key":"2183_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029\u201335.","journal-title":"N Engl J Med"},{"key":"2183_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.gastro.2004.05.010","volume":"127","author":"S Hanauer","year":"2004","unstructured":"Hanauer S, Luk\u00e1\u0161 M, MacIntosh D, Rutgeerts P, Sandborn W, Pollack P. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn\u2019s disease. Gastroenterology. 2004;127:332.","journal-title":"Gastroenterology"},{"issue":"8","key":"2183_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"2183_CR8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2005;353(18):1912\u201325.","journal-title":"N Engl J Med"},{"issue":"21","key":"2183_CR9","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Panes J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388(21):1966\u201380.","journal-title":"N Engl J Med"},{"issue":"20","key":"2183_CR10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"10340","key":"2183_CR11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330.","journal-title":"Lancet"},{"issue":"10340","key":"2183_CR12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031\u201346.","journal-title":"Lancet"},{"issue":"5","key":"2183_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0016-5085(24)05019-4","volume":"166","author":"R Panaccione","year":"2024","unstructured":"Panaccione R, Danese S, Feagan BG, D\u2019Haens G, Afzali A, Reinisch W, et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn\u2019s disease: results of the Galaxi 2 & 3 phase 3 studies. Gastroenterology. 2024;166(5):1057.","journal-title":"Gastroenterology"},{"issue":"10470","key":"2183_CR14","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, Danese S, Chen M, Ghosh S, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404(10470):2423\u201336.","journal-title":"Lancet"},{"issue":"3","key":"2183_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.170.3.827","volume":"170","author":"M Kobayashi","year":"1989","unstructured":"Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170(3):827\u201345.","journal-title":"J Exp Med"},{"issue":"5107","key":"2183_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1126\/science.8097338","volume":"260","author":"CS Hsieh","year":"1993","unstructured":"Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O\u2019Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547\u20139.","journal-title":"Science"},{"issue":"5","key":"2183_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"B Oppmann","year":"2000","unstructured":"Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715\u201325.","journal-title":"Immunity"},{"issue":"3","key":"2183_CR18","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","volume":"278","author":"S Aggarwal","year":"2003","unstructured":"Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910\u20134.","journal-title":"J Biol Chem"},{"issue":"5","key":"2183_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1172\/JCI200317464","volume":"112","author":"C Becker","year":"2003","unstructured":"Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Investig. 2003;112(5):693\u2013706.","journal-title":"J Clin Investig"},{"issue":"7357","key":"2183_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature10228","volume":"475","author":"E Esplugues","year":"2011","unstructured":"Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514\u20138.","journal-title":"Nature"},{"issue":"5804","key":"2183_CR21","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461\u20133.","journal-title":"Science"},{"issue":"16","key":"2183_CR22","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"issue":"10148","key":"2183_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"1","key":"2183_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2183_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D\u2019Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease. N Engl J Med. 2024;391(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"2183_CR26","doi-asserted-by":"crossref","unstructured":"Bourgonje AR, Ungaro RC, Mehandru S, Colombel JF. Targeting the interleukin 23 pathway in inflammatory bowel disease. Gastroenterology. 2024;168(1):29-52.e3.","DOI":"10.1053\/j.gastro.2024.05.036"},{"issue":"10463","key":"2183_CR27","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","volume":"404","author":"V Jairath","year":"2024","unstructured":"Jairath V, Acosta Felquer ML, Jaihyun CR. IL-23 inhibition for chronic inflammatory disease. Lancet. 2024;404(10463):1679\u201392.","journal-title":"Lancet"},{"issue":"10","key":"2183_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/ecco-jcc\/jjy099","volume":"12","author":"S Visvanathan","year":"2018","unstructured":"Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn\u2019s disease: results from a randomized phase II biopsy sub-study. J Crohns Colitis. 2018;12(10):1170\u20139.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2183_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(3):537-49.e10.","journal-title":"Gastroenterology"},{"issue":"10080","key":"2183_CR30","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D\u2019Haens G, Pan\u00e9s J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699\u2013709.","journal-title":"Lancet"},{"issue":"8","key":"2183_CR31","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/19420862.2019.1664365","volume":"11","author":"C Dumet","year":"2019","unstructured":"Dumet C, Pottier J, Gouilleux-Gruart V, Watier H. Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development. MAbs. 2019;11(8):1341\u201350.","journal-title":"MAbs"},{"issue":"11","key":"2183_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, et al. Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA. 2024;332(11):881\u201397.","journal-title":"JAMA"},{"issue":"2","key":"2183_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","volume":"9","author":"S Danese","year":"2024","unstructured":"Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024;9(2):133\u201346.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2183_CR34","doi-asserted-by":"crossref","unstructured":"Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, et al. Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn's disease: results from the phase 3 GRAVITI study. Gastroenterology. 2025. In press.","DOI":"10.1093\/ecco-jcc\/jjae190.0033"},{"key":"2183_CR35","unstructured":"NCT05242471. A study of combination therapy with guselkumab and golimumab in participants with moderately to severely active Crohn's disease. A phase 2b randomized, double-blind, active-and placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of induction and maintenance combination therapy with guselkumab and golimumab in participants with moderately to severely active Crohn's disease. 2022."},{"issue":"2","key":"2183_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease. Gastroenterology. 2022;162(2):495\u2013508.","journal-title":"Gastroenterology"},{"issue":"4","key":"2183_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","volume":"155","author":"P Rutgeerts","year":"2018","unstructured":"Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease. Gastroenterology. 2018;155(4):1045\u201358.","journal-title":"Gastroenterology"},{"issue":"10342","key":"2183_CR38","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200\u201311.","journal-title":"Lancet"},{"issue":"11","key":"2183_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41575-024-00989-y","volume":"21","author":"C Ma","year":"2024","unstructured":"Ma C, Jairath V, Feagan BG, Peyrin-Biroulet L, Danese S, Sands BE, et al. Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2024;21(11):792\u2013808.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"15","key":"2183_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/1745-6215-15-456","volume":"21","author":"BC Kahan","year":"2014","unstructured":"Kahan BC, Cro S, Dor\u00e9 CJ, Bratton DJ, Rehal S, Maskell NA, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;21(15):456.","journal-title":"Trials"},{"issue":"6","key":"2183_CR41","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","volume":"18","author":"C Kapizioni","year":"2024","unstructured":"Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, et al. Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource. J Crohns Colitis. 2024;18(6):790\u2013800.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2183_CR42","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/ibd\/izad245","volume":"30","author":"N Krugliak Cleveland","year":"2023","unstructured":"Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, et al. Real-world persistence of successive biologics in patients with inflammatory bowel disease: findings from ROTARY. Inflamm Bowel Dis. 2023;30(10):1776\u201387.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2183_CR43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341\u201353.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"10","key":"2183_CR44","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","volume":"14","author":"S Bonovas","year":"2016","unstructured":"Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14(10):1385-97.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2183_CR45","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/apt.16050","volume":"52","author":"A Chupin","year":"2020","unstructured":"Chupin A, Perduca V, Meyer A, Bellanger C, Carbonnel F, Dong C. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289\u201397.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2183_CR46","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/jdv.18042","volume":"36","author":"A Norden","year":"2022","unstructured":"Norden A, Moon JY, Javadi SS, Munawar L, Maul JT, Wu JJ. Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(8):1171\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2183_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2183_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2183_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"10198","key":"2183_CR50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"key":"2183_CR51","doi-asserted-by":"crossref","unstructured":"Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. Gut. 2023;72:264\u201374.","DOI":"10.1136\/gutjnl-2022-328052"},{"key":"2183_CR52","unstructured":"NCT05347095. A study of guselkumab in participants with fistulizing, perianal Crohn's disease. A phase 3, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn's disease. 2022."},{"issue":"11","key":"2183_CR53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","volume":"3","author":"R Atreya","year":"2018","unstructured":"Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018;3(11):790\u2013802.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"5","key":"2183_CR54","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68(5):814\u201328.","journal-title":"Gut"},{"key":"2183_CR55","doi-asserted-by":"crossref","unstructured":"Ferrante M, Peyrin-Biroulet L, Dignass A, Rubin DT, Danese S, D\u2019Haens GR, et al. Clinical and endoscopic improvements with risankizumab induction and maintenance dosing versus placebo are observed irrespective of number of prior failed biologics. United Eur Gastroenterol J. 2022;10(8):101.","DOI":"10.14309\/01.ajg.0000859500.54469.44"},{"issue":"Supplement_1","key":"2183_CR56","doi-asserted-by":"publisher","first-page":"i1575","DOI":"10.1093\/ecco-jcc\/jjad212.0978","volume":"18","author":"A Zinger","year":"2024","unstructured":"Zinger A, Choi D, Choi N, Fear E, Fine Z, Cohen RD, et al. P848 risankizumab effectiveness in ustekinumab-na\u00efve and ustekinumab-experienced patients with Crohn\u2019s disease\u2014real-world data from a large tertiary center. J Crohn\u2019s Colitis. 2024;18(Supplement_1):i1575-i.","journal-title":"J Crohn's Colitis."},{"issue":"7","key":"2183_CR57","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1080\/09546634.2022.2095328","volume":"33","author":"B Strober","year":"2022","unstructured":"Strober B, Armstrong A, Rubant S, Patel M, Wu T, Photowala H, et al. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. J Dermatol Treat. 2022;33(7):2991\u20136.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"2183_CR58","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40744-024-00644-7","volume":"11","author":"P Thilakarathne","year":"2024","unstructured":"Thilakarathne P, Schubert A, Peterson S, Noel W, Patel BP, Hassan F. Comparing efficacy of guselkumab versus ustekinumab in patients with psoriatic arthritis: an adjusted comparison using individual patient data from the DISCOVER and PSUMMIT trials. Rheumatol Ther. 2024;11(2):457\u201374.","journal-title":"Rheumatol Ther."},{"issue":"12","key":"2183_CR59","doi-asserted-by":"publisher","first-page":"2451 e1","DOI":"10.1016\/j.cgh.2024.04.016","volume":"22","author":"M Fumery","year":"2024","unstructured":"Fumery M, Caron B, Hebuterne X, Altwegg R, Roblin X, Stefanescu C, et al. Long-term Outcome of Risankizumab in Crohn\u2019s Disease: a Real-world GETAID Study. Clin Gastroenterol Hepatol. 2024;22(12):2451 e1-8 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2183_CR60","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/ibd\/izad315","volume":"30","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Sabino J, Franchimont D, Cremer A, Busschaert J, D\u2019Heygere F, et al. Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn\u2019s disease: a belgian multicentric cohort study. Inflamm Bowel Dis. 2024;30(12):2289\u201396.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"2183_CR61","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"2183_CR62","doi-asserted-by":"publisher","first-page":"i256","DOI":"10.1093\/ecco-jcc\/jjae190.0134","volume":"19","author":"S Cao","year":"2025","unstructured":"Cao S, Ma K, Deepak P. DOP095 IL-23-activated cells as response biomarkers for risankizumab in Crohn\u2019s disease patients. J Crohn\u2019s Colitis. 2025;19(Supplement_1):i256\u20138.","journal-title":"J Crohn's Colitis."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02183-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02183-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02183-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:02:11Z","timestamp":1748012531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02183-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02183-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"7 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors contributed to the outline. The first draft of the manuscript was written by OMN and VJ. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}